Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for exercise intolerance in heart failure with diastolic dysfunction
ACTRN12614000088640Phase 4Completed
- Sponsor
- Menzies Institute for Medical Research
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4 trial of spironolactone in heart failure (HF) and diastolic dysfunction (2 arms), sponsored by Menzies Institute for Medical Research. Primary endpoints: Exercise capacity and Left ventricular filling pressure. Started Nov 2011; status: completed.
02
Drugs
spironolactone
03
Conditions
heart failure (HF)diastolic dysfunction
Beyond the preview
Go deeper on ACTRN12614000088640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000088640.